Navigation Links
Velcura Therapeutics, Inc. Appoints Industry Executive to Lead Regulatory Affairs
Date:10/15/2007

ANN ARBOR, Mich., Oct. 15 /PRNewswire/ -- Velcura Therapeutics, Inc. has named Jeffrey N. Fellows, a biotechnology regulatory executive with more than 20 years of successful regulatory experience, as Vice President of Regulatory Affairs.

Velcura Therapeutics President and CEO Michael W. Long, PhD, said, "Jeff is a great addition to our senior management team. He will be responsible for our clinical trials applications, regulatory compliance and interactions with the Federal Drug Administration. His more than two decades of experience will be critical in helping Velcura navigate the regulatory path for VEL-0230, our new drug that stimulates bone formation and inhibits bone loss." Dr. Long added, "Jeff's past experience with the Oncology Division at FDA is a definite plus as our initial clinical trial of VEL-0230 in patients will be for treatment for Multiple Myeloma Bone Disease, a blood cancer associated with profound bone loss."

Immediately before joining Velcura Therapeutics, Fellows was Vice President of Regulatory Affairs for Cell Therapeutics, Inc. in Seattle, where for the past three years he was the main liaison with the FDA and responsible for the development of global regulatory strategy and agency filings for the oncology focused company.

Prior to CTI, Fellows worked for Amgen Inc. in Thousand Oaks, CA, and worked in a series of increasingly responsible positions, eventually serving as Director of Regulatory Affairs and Global Regulatory Team Leader in Thousand Oaks, California. There Fellows served on Corporate Global Product Strategy Teams for early- and late-stage development compounds and led Global Regulatory Teams in the United States, Europe, Canada, Australia, and Japan.

After graduation from Oregon State University with a Bachelor of Science in Microbiology, Fellows began his career in regulatory affairs at NeoRx Corporation, where he prepared Investigational New Drug Applications for anti- cancer products. He worked for Synergen, Inc. in Boulder, Colorado, from 1990 until Amgen purchased Synergen in late 1994.

Jeffery Fellows lives in Woodway, Washington, and will work from Velcura's Seattle office.

About Velcura Therapeutics(R), Inc.

Velcura Therapeutics, Inc. is an early-stage biotechnology company headquartered in Ann Arbor, Michigan. Velcura's research focus is to better understand human bone disease and to discover novel therapeutics that restore bone health. Velcura develops highly differentiated therapies for bone disease; specifically, dual-acting therapies that demonstrate both anabolic bone-building and anti- bone-loss activities in a single molecule. Velcura uses its patented platform technologies to discover and optimize compounds that both simulate and inhibit bone growth. Velcura's lead compound, VEL-0230 was identified using these bone assays. More information is at http://www.velcura.com

Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Michael W. Long, Ph.D. http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=49215


'/>"/>
SOURCE Velcura Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. Sharon Ethanol appoints operations director
3. Kyron appoints former AMA chairman to board
4. Brady appoints GE efficiency expert as CTO
5. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
6. Johnson Controls appoints Roell to head EOC
7. SecurePipe appoints two senior execs
8. Milwaukees PointOne appoints new president and CEO
9. Third Wave appoints new chairman
10. Midwest Venture Summit disappoints; Cato grades Midwest governors
11. Sonic Foundry appoints Engineering Dean and Cometa CEO to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... May 24, 2017 , ... Today, the South Davis Sewer ... Biological Nutrient Recovery (ABNRâ„¢) technology at its 4,000,000 gallon per day South Plant. ... sustainably meet current and future nutrient discharge regulations. The ABNR platform, which is ...
(Date:5/23/2017)... ... May 23, 2017 , ... Firmex ... that makes it easy for organizations to send and gather large files and ... software or email file size limitations. , Using the same market-tested infrastructure ...
(Date:5/23/2017)... (PRWEB) , ... May 22, 2017 , ... ... and Photonics 2017 in San Diego, California, this August will feature high-level ... fuels, and autonomous vehicles. , SPIE Optics and Photonics, the largest multidisciplinary optical ...
(Date:5/23/2017)... ... May 23, 2017 , ... Cambridge Semantics , the leading provider ... Bio-IT World Conference and Expo in Boston May 23-25 with a featured ... The Anzo Smart Data Lake is also a finalist for the Best of Show ...
Breaking Biology Technology:
(Date:4/5/2017)... LONDON , April 4, 2017 KEY ... is anticipated to expand at a CAGR of 25.76% ... neurodegenerative diseases is the primary factor for the growth ... full report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The ... of product, technology, application, and geography. The stem cell ...
(Date:3/30/2017)... -- On April 6-7, 2017, Sequencing.com will host the world,s ... at Microsoft,s headquarters in Redmond, Washington ... health and wellness apps that provide a unique, personalized ... is the first hackathon for personal genomics and the ... the genomics, tech and health industries are sending teams ...
(Date:3/29/2017)... 29, 2017  higi, the health IT company that ... North America , today announced a Series B ... of EveryMove. The new investment and acquisition accelerates higi,s ... to transform population health activities through the collection and ... higi collects and secures data today on behalf ...
Breaking Biology News(10 mins):